company background image

Rani Therapeutics Holdings NasdaqGM:RANI Stock Report

Last Price


Market Cap







12 Aug, 2022


Company Financials +
RANI fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health6/6

RANI Stock Overview

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics.

Rani Therapeutics Holdings, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Rani Therapeutics Holdings
Historical stock prices
Current Share PriceUS$11.32
52 Week HighUS$36.27
52 Week LowUS$8.00
1 Month Change-5.82%
3 Month Change2.91%
1 Year Change-39.17%
3 Year Changen/a
5 Year Changen/a
Change since IPO2.91%

Recent News & Updates

Aug 08

Rani Therapeutics enters $45M loan agreement to support advancement and pipeline development

Rani Therapeutics (NASDAQ:RANI) enters a loan agreement with Avenue Venture Opportunities Fund for up to $45M of funding. This financing is expected to support the continued advancement of the RaniPill platform and ongoing clinical development of the company’s drug pipeline. Under the loan agreement, company will receive $15M of the initial $30M tranche at closing, with the remaining $15M available for draw at the company’s discretion in Q4 2022. Company has the right to request an additional $15M of funds in the future if certain conditions and milestones are met. Interest at a variable rate equal to the greater of (1) prime, plus 5.6% and (2) 10.35%

Shareholder Returns

RANIUS PharmaceuticalsUS Market

Return vs Industry: RANI underperformed the US Pharmaceuticals industry which returned 0.7% over the past year.

Return vs Market: RANI underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is RANI's price volatile compared to industry and market?
RANI volatility
RANI Average Weekly Movement14.3%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: RANI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: RANI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

2012114Talat Imran

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes.

Rani Therapeutics Holdings, Inc. Fundamentals Summary

How do Rani Therapeutics Holdings's earnings and revenue compare to its market cap?
RANI fundamental statistics
Market CapUS$480.23m
Earnings (TTM)-US$22.18m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RANI income statement (TTM)
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$22.18m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.91
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did RANI perform over the long term?

See historical performance and comparison